Home > Cardiology > ISTH 2020 > Haemophilia and Rare Bleeding Disorders > Haemophilia gene therapy: progress and obstacles

Haemophilia gene therapy: progress and obstacles

Presented By
Prof. Amit Nathwani, University College London, United Kingdom
Conference
ISTH 2020
Trial
Review study
The future of gene therapy for haemophilia patients looks bright. Prof. Amit Nathwani (University College London, United Kingdom) presented a review of promising gene therapy trial results in haemophilia B and A [1]. Among vectors of viral origin, and as far as is known to date, adeno-associated virus (AAV) vectors have the best safety profile. “AAV vectors can integrate into the host DNA but at frequencies that are quite low,” Prof. Nathwani explained. However, this integration has only been shown in animal studies until today. A single administration of AAV vectors leads to stable long-term expression of transgenic protein. Haemophilia B: fewer factor concentrates necessary AAV comes in a variety of different serotypes (e.g. AAV2, AAV5, AAV8, AAV9) and selection of the most suitable capsid is required. For example, Prof. Nathwani and colleagues selected an...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on